Platinum anticancer drugs. From serendipity to rational design

Monneret, Claude

doi:10.1016/j.pharma.2011.10.001

Cited by 147 publications

(136 citation statements)

References 50 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…As it stands, however, neither picoplatin- nor satraplatin-containing regimens provide consistent advantages over CDDP-, oxaliplatin- and carboplatin-based chemotherapy. 37, 38, 39, 40 Thus, the interest in developing novel platinum derivatives as well as clinically applicable strategies to increase the sensitivity of human neoplasms to CDDP remains high.…”

Section: Open Questionsmentioning

confidence: 99%

Systems biology of cisplatin resistance: past, present and future

Vitale²,

et al. 2014

View full text Add to dashboard Cite

The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the administration of cisplatin is generally associated with high rates of clinical responses. However, in the vast majority of cases, malignant cells exposed to cisplatin activate a multipronged adaptive response that renders them less susceptible to the antiproliferative and cytotoxic effects of the drug, and eventually resume proliferation. Thus, a large fraction of cisplatin-treated patients is destined to experience therapeutic failure and tumor recurrence. Throughout the last four decades great efforts have been devoted to the characterization of the molecular mechanisms whereby neoplastic cells progressively lose their sensitivity to cisplatin. The advent of high-content and high-throughput screening technologies has accelerated the discovery of cell-intrinsic and cell-extrinsic pathways that may be targeted to prevent or reverse cisplatin resistance in cancer patients. Still, the multifactorial and redundant nature of this phenomenon poses a significant barrier against the identification of effective chemosensitization strategies. Here, we discuss recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem.

show abstract

Section: Open Questionsmentioning

confidence: 99%

Systems biology of cisplatin resistance: past, present and future

Vitale²,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Within this group, the 3 agents most frequently involved in hypersensitivity reactions are cisplatin, carboplatin, and oxaliplatin [5]. Cisplatin is currently less used due to its toxicity profile [6]; carboplatin is especially prescribed in gynecological cancers, namely ovarian carcinoma [7]; and oxaliplatin is one of the main drugs used in the treatment of colorectal cancer [7,8]. Regarding the immune mechanism underlying hypersensitivity reactions to platins, the IgE-mediated mechanism is considered predominant; it is sustained by the sudden onset of symptoms during or shortly after infusion of the drug and previous sensitization due to multiple exposures until the onset of the reaction [5].…”

Section: Introductionmentioning

confidence: 99%

The Contribution of the Basophil Activation Test to the Diagnosis of Hypersensitivity Reactions to Oxaliplatin

Ornelas

Caiado

Melo

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Cytostatics, mainly oxaliplatin, are widely used to treat oncological diseases. There has been an increase in hypersensitivity reactions to these drugs, mostly IgE-mediated. Skin tests are the main diagnostic method used but they may induce irritant local reactions and contamination by health care professionals. The main goals of this work were to evaluate the contribution of the basophil activation test (BAT) as a diagnostic tool for hypersensitivity reactions to oxaliplatin, and to compare the expression of CD63 and CD203c molecules. BAT was performed with oxaliplatin in 6 oncological patients with previous documented hypersensitivity reactions to oxaliplatin and in 5 controls (4 oncological patients tolerant to oxaliplatin and 1 healthy control), assessing CD63 and CD203c expression on basophil population. We found higher values for the basophil activation percentage and mean stimulation index for CD203c expression with all oxaliplatin concentrations tested (most significant at 150 μg/mL: p = 0,0087; p = 0.0222) in the patients than in controls. The same did not occur, with statistical significance, for CD63 expression. When we compared the 2 activation markers in the patients, we observed a more enhanced expression of CD203c in both evaluations, with statistical significance at the 150-μg/mL concentration (p = 0,026; p = 0,0129). These data show a higher positivity of BAT with oxaliplatin in patients with previous hypersensitivity reactions, when compared to controls, suggesting that BAT may be a promising diagnostic method as an alternative to skin tests. CD203c appears to play a more prominent role than CD63, which is consistent with what is published in the literature.

show abstract

“…Cisplatin remains a major chemotherapeutic agent for the treatment of solid tumors (13). Its chief dose-limiting side effect is nephrotoxicity, which evolves slowly and predictably over the course of administration.…”

Section: Discussionmentioning

confidence: 99%

The safety and effect of chemotherapy with short hydration for urothelial cancer on patients’ quality of life

Azuma

Matayoshi

Sato

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Our aim was 2-fold: first, to assess the safety of short hydration treatment for urothelial cancer; and second, to assess the resultant quality of life of patients who received the treatment. Methods: We assessed 61 patients including 31 outpatients and 30 inpatients, who received a combination of gemcitabine and cisplatin chemotherapy with short hydration. The serum creatinine (Cr) level and the estimated glomerular filtration rate were measured to assess renal function using linear mixed model analysis. To assess quality of life, the patients were asked to respond to the Functional Assessment of Cancer Therapy-General questionnaire. The responses were then analyzed using the paired t-test. Results: Patients who received short hydration chemotherapy showed no significant change in serum Cr level (P = 0.423) or estimated glomerular filtration rate (P = 0.582). There was also no significant change in serum Cr level or estimated glomerular filtration rate between patients who received short hydration chemotherapy and those who received consecutive hydration chemotherapy (P = 0.154 and 0.311, respectively). In every patient, the Functional Assessment of Cancer Therapy-General total score and subscale scores both improved as a result of outpatient chemotherapy with short hydration (P < 0.01). Conclusions: The short hydration gemcitabine and cisplatin regimen for patients with urothelial cancer was safe. Further, the outpatient chemotherapy was found not only to be safe, but also to have improved the patients' quality of life.

show abstract

Platinum anticancer drugs. From serendipity to rational design

Cited by 147 publications

References 50 publications

Systems biology of cisplatin resistance: past, present and future

Systems biology of cisplatin resistance: past, present and future

The Contribution of the Basophil Activation Test to the Diagnosis of Hypersensitivity Reactions to Oxaliplatin

The safety and effect of chemotherapy with short hydration for urothelial cancer on patients’ quality of life

Contact Info

Product

Resources

About